UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 75

Sortiert nach

Safety and efficacy of apixaban versus vitamin K antagonists in patients undergoing dialysis: a systematic review and meta-analysis

Renal failure, 2024-12, Vol.46 (1), p.2349114-2349114

2024

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US

Journal of medical economics, 2022-12, Vol.25 (1), p.309-320

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries

Expert opinion on drug safety, 2023-06, Vol.22 (6), p.493-500

2023

Link zum Volltext

Verfügbarkeit prüfen

Drug interactions with new oral anticoagulants in elderly patients

Expert review of clinical pharmacology, 2017-11, Vol.10 (11), p.1191-1202

Stöllberger, Claudia

2017

Link zum Volltext

Verfügbarkeit prüfen

A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK

Current medical research and opinion, 2023-03, Vol.39 (3), p.483-495

2023

Link zum Volltext

Verfügbarkeit prüfen

An update on hip fracture risk associated with anticoagulant therapy: warfarin versus direct oral anticoagulants

Expert opinion on drug safety, 2020-10, Vol.19 (10), p.1219-1220

Sugiyama, Toshihiro

2020

Link zum Volltext

Verfügbarkeit prüfen

Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice

Expert opinion on drug safety, 2020-11, Vol.19 (11), p.1513-1520

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism

Expert opinion on drug safety, 2019-04, Vol.18 (4), p.313-320

2019

Link zum Volltext

Verfügbarkeit prüfen

A comprehensive evaluation of apixaban in the treatment of venous thromboembolism

Expert review of hematology, 2020-02, Vol.13 (2), p.155-173

2020

Link zum Volltext

Verfügbarkeit prüfen

How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: model-informed remedial dosing

Expert review of clinical pharmacology, 2021-09, Vol.14 (9), p.1153-1163

2021

Link zum Volltext

Verfügbarkeit prüfen

Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment

Expert review of hematology, 2021-04, Vol.14 (4), p.335-346

2021

Link zum Volltext

Verfügbarkeit prüfen

Managing patients on direct factor Xa inhibitors with rapid thrombelastography

Scandinavian journal of clinical and laboratory investigation, 2021-12, Vol.81 (8), p.661-669

2021

Link zum Volltext

Verfügbarkeit prüfen

A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers

Xenobiotica, 2017-07, Vol.47 (7), p.592-599

2017

Link zum Volltext

Verfügbarkeit prüfen

Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition

Expert review of clinical pharmacology, 2020-07, Vol.13 (7), p.695-706

2020

Link zum Volltext

Verfügbarkeit prüfen

A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention

Expert opinion on drug safety, 2019-12, Vol.18 (12), p.1119-1125

2019

Link zum Volltext

Verfügbarkeit prüfen

Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults

Expert review of pharmacoeconomics & outcomes research, 2018-07, Vol.18 (4), p.371-377

2018

Link zum Volltext

Verfügbarkeit prüfen

Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors

Expert review of cardiovascular therapy, 2017-04, Vol.15 (4), p.237-245

2017

Link zum Volltext

Verfügbarkeit prüfen

Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants

Journal of medical economics, 2020-12, Vol.23 (12), p.1409-1417

2020

Link zum Volltext

Verfügbarkeit prüfen

Rivaroxaban Use in Patients with Hemoglobinopathies

Hemoglobin, 2017-05, Vol.41 (3), p.223-224

2017

Link zum Volltext

Verfügbarkeit prüfen

Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism: A Prospective Cohort Study of 12 Patients

Hemoglobin, 2019-09, Vol.43 (4-5), p.296-299

2019

Link zum Volltext

Verfügbarkeit prüfen

The safety of edoxaban for treating atrial fibrillation

Expert opinion on drug safety, 2017-11, Vol.16 (11), p.1295-1303

2017

Link zum Volltext

Verfügbarkeit prüfen

Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies

Expert opinion on drug safety, 2017-02, Vol.16 (2), p.113-124

2017

Link zum Volltext

Verfügbarkeit prüfen

Ophthalmic Complications Associated with Direct Oral Anticoagulant Medications

Seminars in ophthalmology, 2017-09, Vol.32 (5), p.614-619

2017

Link zum Volltext

Verfügbarkeit prüfen

Andexanet alfa for the treatment of hemorrhage

Expert review of hematology, 2018-11, Vol.11 (11), p.847-855

2018

Link zum Volltext

Verfügbarkeit prüfen

Dosing of rivaroxaban by indication: getting the right dose for the patient

Expert opinion on drug metabolism & toxicology, 2015-10, Vol.11 (10), p.1665-1677

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 75

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis Online

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(75)

Sprache

Englisch
(75)
Japanisch
(7)

Erscheinungsjahr

n.n

Kollektion

MEDLINE
(75)
Taylor & Francis
(75)
Taylor & Francis Journals Auto-Holdings Collection
(71)
Journals@Ovid Full Text
(20)
Elektronische Zeitschriftenbibliothek
(8)
IngentaConnect Journals
(5)
IngentaConnect
(5)
NUS Single-Journal Subscriptions
(4)

3 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of apixaban versus vitamin K antagonists in patients undergoing dialysis: a systematic review and meta-analysis

Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US

Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries

Drug interactions with new oral anticoagulants in elderly patients

A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK

An update on hip fracture risk associated with anticoagulant therapy: warfarin versus direct oral anticoagulants

Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice

Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism

A comprehensive evaluation of apixaban in the treatment of venous thromboembolism

How to handle the delayed or missed dose of rivaroxaban in patients with non-valvular atrial fibrillation: model-informed remedial dosing

Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment

Managing patients on direct factor Xa inhibitors with rapid thrombelastography

A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers

Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition

A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention

Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults

Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors

Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants

Rivaroxaban Use in Patients with Hemoglobinopathies

Use of Direct Oral Anticoagulants in Patients with Sickle Cell Disease and Venous Thromboembolism: A Prospective Cohort Study of 12 Patients

The safety of edoxaban for treating atrial fibrillation

Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies

Ophthalmic Complications Associated with Direct Oral Anticoagulant Medications

Andexanet alfa for the treatment of hemorrhage

Dosing of rivaroxaban by indication: getting the right dose for the patient

Aktive Filter

Suchergebnisse filtern